![Stephen A. Roth](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen A. Roth
Directeur/Bestuurslid bij AppTec Laboratory Services, Inc.
Profiel
Dr. Roth is currently CEO of Immune Control, an early stage biotechnology company.
He was a Co-Founder and former Chairman and CEO of Neose Technologies, Inc. Previously, he was Professor and Chairman of the Biology Department at University of Pennsylvania.
He currently serves as member of the advisory boards of the Schools of Arts and Sciences at Case Western Reserve University and the University of Pennsylvania.
Dr. Roth is a director of AppTec Laboratory Services, Inc. and VioQuest Pharmaceuticals, Inc.
Actieve functies van Stephen A. Roth
Bedrijven | Functie | Begin |
---|---|---|
AppTec Laboratory Services, Inc.
![]() AppTec Laboratory Services, Inc. Miscellaneous Commercial ServicesCommercial Services AppTec Laboratory Services, Inc. provides testing services to the biopharmaceutical and medical device industries. The company's services include testing, contract R&D, cGMP manufacturing, tissue-based, combination products, and cellular therapeutics. The company was founded by Bonita L. Baskin in 1989 and is headquartered in St. Paul, MN. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Stephen A. Roth
Bedrijven | Functie | Einde |
---|---|---|
Immune Control, Inc.
![]() Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | President | 06-12-2012 |
Quaker Partners Management LP
![]() Quaker Partners Management LP Investment ManagersFinance Quaker Partners Management LP (Quaker Partners Mgmt) is a venture capital subsidiary of Independence Capital Partners Inc founded in 2002 by Ira Mark Lubert and Paul Sherrill Neff. The firm is headquartered in Philadelphia, Pennsylvania. | Private Equity Investor | 30-03-2010 |
Great Expectations & Associates, Inc. | Directeur/Bestuurslid | 07-01-2005 |
VIOQUEST PHARMACEUTICALS, INC. | Directeur/Bestuurslid | - |
University of Pennsylvania | Corporate Officer/Principal | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
VIOQUEST PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 5 |
---|---|
Great Expectations & Associates, Inc. | Health Technology |
Immune Control, Inc.
![]() Immune Control, Inc. Pharmaceuticals: MajorHealth Technology Immune Control is an emerging pharmaceutical company developing novel, orally available, small molecules for autoimmune/inflammatory diseases. The company is commercializing the discovery that serotonin is a required growth factor for dividing lymphocytes. Certain serotonin antagonists eliminate activated or dividing T- or B-lymphocytes without disturbing resting lymphocytes. The ability to kill activated immune cells selectively has important implications for treating autoimmune/inflammatory diseases, hematologic cancers, and organ transplant rejection. Immune Control is a first-mover and the leader in the emerging field of serotonin-based immunotherapeutics. Their preclinical development program has yielded important insights into the design of orally available, potent, small molecules for autoimmune/inflammatory conditions. Immune Control is focused initially on two diseases: rheumatoid arthritis and asthma. Immune Control designs and develops novel compounds using in vitro and in vivo assays for receptor binding, efficacy, safety, and bioavailability. In 2008, the company plans to nominate two compounds as IND candidates for RA and asthma. In addition, they are conducting phase 1, proof-of-concept clinical trials in multiple myeloma and psoriasis, utilizing a currently approved serotonin antagonist. | Health Technology |
Quaker Partners Management LP
![]() Quaker Partners Management LP Investment ManagersFinance Quaker Partners Management LP (Quaker Partners Mgmt) is a venture capital subsidiary of Independence Capital Partners Inc founded in 2002 by Ira Mark Lubert and Paul Sherrill Neff. The firm is headquartered in Philadelphia, Pennsylvania. | Finance |
Neose Technologies, Inc.
![]() Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
AppTec Laboratory Services, Inc.
![]() AppTec Laboratory Services, Inc. Miscellaneous Commercial ServicesCommercial Services AppTec Laboratory Services, Inc. provides testing services to the biopharmaceutical and medical device industries. The company's services include testing, contract R&D, cGMP manufacturing, tissue-based, combination products, and cellular therapeutics. The company was founded by Bonita L. Baskin in 1989 and is headquartered in St. Paul, MN. | Commercial Services |